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ABSTRACT
Background Leukaemia is the most prevalent form of
cancer-causing death in a large number of populations and
needs prompt and effective treatment. Chemotherapeutics
can be used to treat leukaemia, but their pronounced killing
effects to other living cells is still an issue. Active targeting to
certain specific receptors in leukaemic cells is the best way to
avoid damage to other living cells. Leukaemic cells can be
targeted using novel nanoparticles (NPs) coated with a specific
ligand, such as octreotide (OCD), to target somatostatin re-
ceptor type 2 (SSTR2), which is expressed in leukaemic cells.
Methods Amino-PEGylated quantum dots (QDs) were cho-
sen as model NPs. The QDs were first succinylated using
succinic anhydride and then coated with OCD. The reactivity
and selectivity of the formulated QDs-OCD were studied in
cell lines with well-expressed SSTR2, while fluorescence was
detected using confocal laser scanning microscopy (CLSM)
and flow cytometry (FACS). Conclusively, QD-OCD target-
ing to blood cells was studied in vivo in mice and detected using
inductively coupled plasma mass spectrometry and CLSM in
tissues.
Results Highly stable QDs coated with OCD were prepared.
FACS and CLSM showed highly definite interactions with
overexpressed SSTR2 in the investigated cell lines.
Moreover, the in vivo results revealed a higher concentration
of QDs-OCD in blood cells. The fluorescence intensity of the
QDs-OCD was highly accumulated in blood cells, while the
unmodified QDs did not accumulate significantly in blood
cells. Conclusion: The formulated novel QDs-OCD can tar-
get SSTR2 overexpressed in blood cells with great potential
for treating blood cancer.
KEY WORDS fluorescent nanoparticles, leukaemia, active
targeting . octreotide . PEGylated quantum dots . somatostatin
receptors
INTRODUCTION
Leukaemia is a kind of blood cancer that begins in the bone
marrow (19,21). This type of malignant cell is caused by the
anomalous circulation of undeveloped white blood cells,
which multiply in an uncontrolled manner. Leukaemia can
likewise emerge in young people, and the most common form
is called acute lymphoid leukaemia characterised by expan-
sion of one cell type, whereas other cells responsible for the
defence or for the oxygen transport becoming less (18,25).
Leukaemia starts in the blood and it can spread to other
organs of the body, such as lymph nodes, liver, spleen, central
nervous system and other organs (16,41). Effective targeting of
chemotherapeutic medications to the places containing
tumours could be a great advantage to patients with advanced
metastatic tumours (54). Cytotoxic compounds linked to
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analogues of hormonal peptides could be an essential addition
to oncological medical practitioners (4). Leukaemic cells with-
in the body carry surface receptors that are specific for their
particular type of cell. Somatostatin (SST) and its analogues
and receptors play an important role in the proliferation of
leukaemic cells as previously reported (31,44). Somatostatin
receptors are five subtypes (SSTR1–5) have been detected in
peripheral blood lymphocytes (PBLs) and mammalian leukae-
mic cells in lymphoblastic and nonlymphocytic leukaemia via
somatostatin radio binding assays (28). The frequent incidence
of SSTR2 in tumour cells makes SSTR2 a promising target for
antitumor therapy. SSTR2 are abundantly present on the
membrane of leukaemic cells. Thus, leukaemic cells can be
easily detected and targeted using nanoparticulate systems
coated with somatostatin analogues such as vapreotide
(VAP) or octreotide (OCD) for efficient therapy and early
detection (29,56).
Nanoparticles are used as carriers for drug delivery,
either by encapsulating an active substance or by phys-
ical or chemical absorption of drugs, which enable the
nanoparticle to reach the cell surface easily (5,15).
Specific drug targeting to different body organs has nu-
merous advantages for more efficient drug treatment
compared with conventional therapy (4). Additionally,
active binding has shown a significantly lower incidence
of side effects and other toxic manifestations (13). QDs
are semiconductor NPs unaffected by photobleaching
with high stability in blood; hence, QDs have wide
applications in vivo (7). Furthermore, QDs are well tol-
erated in different cell lines, and due to their unique
properties derived from their size and structure, they
could be used for detection, bioimaging, and targeting
purposes (7–9).
Octreotide (OCD) is an effective SST analogue that
shows higher internalization into cells with more SSTR2
on their surfaces compared with natural SST.
Moreover, OCD can be easily attached to NPs to target
different cancer cells. Almost all of the OCD can be
conjugated to amine PEGylated QDs as a surrogate
for PEGylated NPs to specifically target normal and
diseased cells overexpressing SSTR2 (24,62).
The purpose of this work was to study the potential
of modified QDs with SST analogues to target SSTR2
located in blood cells for efficient treatment and early
diagnosis of leukaemia. QD-PEG-amine was first conju-
gated to OCD using 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide (EDC) and N-hydroxysuccinimide (NHS).
The selectivity of the formulated QDs-OCD for SSTR2
was studied in different cell lines with well-expressed
SSTR1–5. Moreover, the fluorescence was detected using
CLSM and FACS. The targeting of QDs-OCD to




Octreotide acetate was obtained from ChemPep Co.
(Wellington, USA). Quantum dots-PEG-amino (Qdot® 655
ITK™ amino (PEG) quantum dots), Dulbecco’s phosphate-
buffered saline (pH 7.4), Dulbecco’s modified Eagle’s medi-
um, and Leibovitz’s L-15 medium were purchased from Life
Technology (Darmstadt, Germany). Succinic anhydride, 1-
ethyl-3-(3-dimethylaminopropyl) carbodiimide, nitric acid,
hydrochloric acid, Sephadex G-25, and N,N-diisopropylethyl-
amine (DIPEA) were purchased from Sigma Aldrich
(Darmstadt, Germany). Ultrafiltration tubes (100-kDa,
Ultra-4 Millipore) were obtained from Amicon (Billerica,
USA). Pancreatic carcinoid tumour cells were kindly supplied
by Novartis Institutes (Basel, Switzerland). All glassware was
carefully washed with freshly prepared aqua regia (HCl:
HNO3, 3:1), rinsed with Millipore water and oven-dried at
40°C for 3–4 h before use.
Conjugation of Octreotide to QDs
QDs-OCD were obtained by conjugating Qdot® 655 ITK™
amino (PEG) quantum dots, (unmodifiedQDs) toOCD at the
N-terminus of OCD (43) at pH 8.0 as adjusted with DIPEA.
Succinic anhydride was reacted with QDs to form succiny-
lated QDs using EDC as a water-soluble cross-linker (Fig. 1)
(36,57). For succinylation of the QDs, solid succinic anhydride
(equimolar) was added to 15 μL of 8.0 μMQDs plus 2 mL of
phosphate buffer at pH 9.0 and stirred at 600 rpm for 15 min.
The reaction proceeded for 1 h. The excess succinic anhy-
dride was removed using Sephadex G-25 followed by centri-
fugation at 1800×g for 5 min (35,51). Furthermore, the
obtained succinylated QDs were resuspended in 500 μL of
water. Afterward, 100 μL of 0.6 μM OCD was added to the
reaction mixture, incubated with 0.45 μMEDC and 0.22 μM
NHS and stirred for an additional 3 h at room temperature.
The final product, QDs-OCD, was filtered using Sephadex
G-25 and then centrifuged at 1800×g for 10 min at 20°C (57).
Quantum Dot Characterization
The sizes and zeta potentials of the unmodified QDs and
QDs-OCD were determined using a Malvern Zetasizer
Nano ZS (Malvern Instruments GmbH, Herrenberg,
Germany). Moreover, infrared spectra were recorded using
a Bruker Tensor 27 Optics (Bruker BioSpin GmbH,
Rheinstetten, Germany). Spectra were collected in the range
of 400–4000 cm−1 using attenuated total reflectance Fourier
transform infrared spectroscopy (ATR-FTIR) (10). For 1H-
NMR measurements, QDs were dried under vacuum and
then dissolved in 750 μL D2O using a Bruker DRX400 or
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AC300 autosampler spectrometer operating at 300 MHz, re-
spectively (Bruker Electronik, Rheinstetten, Germany).
Chemical shifts (δ in ppm) are given relative to tetramethylsi-
lane (TMS= 0 ppm), as an internal reference standard.
Cellular Uptake Study
Human pancreatic NET (BON-1) cells andHenrietta Lack fam-
ily (HeLa) cells were chosen as models of positive SSTR expres-
sion, and the human primary glioblastoma cell line U-87 was
chosen as a model of negative SSTR expression. Cells were
seeded in a 24-well plate in growth medium and permitted to
mature for 3 days at a density of 100,000 cells/well. Then, the
cells were incubated with 20 nM QDs, QDs-OCD, or QDs-
OCD+100 μM freeOCD for 3 h at 37°C. The dose was single
dose as previously reported protocol by our lab Hennig et al. (27).
After incubation, the cells were washed with Dulbecco’s
phosphate-buffered saline (DPBS), trypsinized, and centrifuged
at 300×g at 4°C. FACSwas used to identify the internalization of
QDs-OCD at 488 and 655 nm as the excitation and emission
wavelengths, respectively. Fluorometric analysis was performed
to obtain the concentration of QDs using an LS-55 Perkin Elmer
Spectrometer (Waltham, USA) with excitation and emission
wavelengths of 488 and 655 nm, respectively (17,49). To analyse
the displacement of QDs-OCD from the targeted cells, approx-
imately 10,000 cells were seeded into 8-well Ibed chamber slides
(Berlin, Germany). A competitive displacement investigation was
carried out by mixing the QDs-OCD with a 100 μM of free
OCD for 1 h at 37°C (49). Then, the cells were investigated
using a Zeiss Axiovert 200 M inverted epifluorescence micro-
scope (Munich, Germany) with 488 nm/655 nm as the excita-
tion and emission wavelengths, respectively (7).
Animal Study
Animal handling andwork were approved and performed under
the relevant guidelines and regulations by Regierung der
Oberpfalz, reference no. 54–2532, 1–23/11. Male albino mice
with a bodyweight of 35–40± 0.5 g and an age of approximately
4–5months were used for the in vivo study, as previously reported
by Pollinger et al. (50). Each mouse was injected intraperitoneally
(IP) with 55 μL of a mixture of ketamine and xylazine (3:1). The
reported doses of ketamine and xylazine were 100 mg/kg and
10 mg/kg, respectively (37). Then, mice were injected with QDs
and QDs-OCD (100 pmole) into the lateral vein (50). One hour
post-injection, the mice were sacrificed, and the organs were
fixed with 4% PFA and left overnight. The kidney, eyes, colon,
lung, heart, pancreas, and liver were obtained and fixed in tissue-
Tek gel after being frozenwith liquid nitrogen, and then stored at
−40± 0.5°C. The obtained organs were cut into 10 μm-thick
slices using a cryotome. Then, the organ sections were displayed
on charged slides from Fisher Scientific (Pittsburgh, USA) and
imaged by CLSM (7).
Determination of Cadmium Mass. The distribution of QDs-
OCD was studied by quantifying the amount of cadmi-
um (Cd) in all organs using a 7700cx inductively coupled
plasma mass spectrometry (ICP-MS) instrument (Agilent
Technologies, Santa Clara, USA) as described in previ-
ous studies (34,60). Briefly, samples were harvested,
washed in DPBS, and digested using the microwave-
assisted nitric acid digestion method (MARSX press sys-
tem (CEM)). The content of Cd quantitatively repre-
sented the number of QDs in all tissues. The total
injected dose (ID) was calculated by adding the Cd mass
of all organs (7).
Fig. 1 Conjugation of QDs-PEG-
amine (unmodified QDs) with
OCD, the amino group of the QDs
was succinylated and then
conjugated to OCD.
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Determination of Blood Fluorescent QDs-OCD. The amount of
internalized QDs-OCD in the blood cells was determined by
centrifugation of the blood samples at 5000 rpm, and the
resulting blood serum was used. The fluorescence of the un-
modified QDs and QDs-OCD was recorded using a Perkin-
Elmer LS 55 (Rodgau, Germany) (11).
Statistical Analysis. ANOVA was performed to study the sta-
tistics of the generated data using Minitab 17 statistical soft-
ware with Tukey’s comparison model. Statistical analysis was
conducted for the cellular uptake and animal work.
Statistically, significance was recorded when p ≤ 0.05.
RESULTS
QDs Characterization
A stable QDs-OCD nanoparticle solution was obtained and
confirmed from the pronounced fluorescence emission spectra
with a slight non-significant blueshift compared with the QDs
alone. The observed blueshift was attributed to the conjuga-
tion of QDs with OCD. In addition, the particle diameter size
for the QDs-OCD was 283.3 ± 17.0 nm compared to 267.0
± 23.0 nm for GEG amine due to coating with OCD as mea-
sured by the Zetasizer Nano. Furthermore, a zeta potential
study revealed successful conjugation between the QDs and
OCD, as revealed by inversion of the zeta potential value.
Unmodified QDs and QDs coated with OCD showed inver-
sion of the zeta potential value from negative (−22.4 ±
0.56 mV) for unmodified QDs to positive for QDs-OCD
(+11.5 ± 0.27 mV). The zeta potential value indicated the
stability of the produced nanoparticle dispersion (26).
The conjugation of QDs with OCD was finally proved using
1H-NMR spectroscopy. 1H-NMR spectra of OCD, QDs and
QDs-OCD in deuterated methanol (CD3OD) are illustrated in
(supplementary data S1). 1H-NMR proved the successful func-
tionalization of QDs carrying PEG-amine end groups with suc-
cinic anhydride. The modification of the amine group of QDs-
PEG-amine (unmodified) by succinic anhydride is characterized
by the appearance of succinate peaks beside those of PEG.
Succinate protons were used as internal standard (area I, at 2.5–
2.8 ppm). Additionally, the PEG protons were detected in the
region of area II at 3.4–3.8 ppmbefore and after conjugation with
OCD, confirming the stability of QDs during the process of con-
jugation. The aromatic peaks at 7.00–7.50 ppm (area III) were
used as indicator for the presence of OCD conjugated to QDs.
However, the product showed also the presence of some
impurities such as methanol or water. This is due to the in-
complete process of purification of unmodified and formulat-
ed QDs which could not be further confirmed, since the QDs-
OCD are very sensitive to the harsh purification and drying
procedure which may damage the nanoparticles. The
coupling reaction of QDs and OCD was completed after
3 h. However, further investigations are needed to further
support this characterization.
FT-IR was used to measure the functional groups of
the polymers and peptides decorated nanoparticles
(12,20,22,23,32). The main bands of OCD, unmodified
QDs, QDs-OCD and physical mixture of QDs & OCD
spectra of the dried samples are shown in (supplementary
data S2). The corresponding spectra were smoothened
and normalized in order to define the most important
bands (S2). FT-IR showed significant differences in the
shape and position of peaks between of QDs-OCD and
a physical mixture of QDs & OCD. QDs-OCD exhibit
sharp bands at 1634.6 cm−1 and 1564.4 cm−1, which
can be attributed to the presence of (C=O stretching) of
amide group and appearing of sharp bands at 1490 cm−1
and 1500 cm−1 which is attributed to the presence of (N-
H bending) of amide group. The amide bond is formed
during the conjugation of OCD to the carboxylic group of
succinylated-Qdots. These two distinct bands were found
only for QDs-OCD and not in the physical mixture.
These findings confirm the successful reaction of conjuga-
tion of QDs with OCD using EDC. The bands at
3300 cm−1, are corresponding to N-H stretching vibra-
tions of NH2 from the Lys of OCD. These mean that
NH2 of the Lys side chain of OCD does not interact with
unmodified QDs (QDs-PEG amine), which is still free.
Cellular Uptake Study
The cellular uptake study revealed that unmodified QDs did not
show any significant uptake when tested in BON-1 cells (Fig. 2, a
and b), whereas QDs-OCD showed significant uptake (p ≤ 0.05,
ANOVA/Tukey) with strong fluorescence (Fig. 2, c). The fluo-
rescence of the QDs-OCD appeared as spots in the cytoplasm of
the cells due to receptor-mediated endocytosis. This observation
suggested the effective targeting of the produced particles into
their targeted cells. Interestingly, internalization was reduced af-
ter the addition of 100 μM OCD as a free agonist, which dis-
placed the QDs-OCD (Fig. 2, d). The active internalization of
QDs-OCD into the other cell lines was also studied, e.g., HeLa
cells and U-87 cells, and the results were compared with those
from the BON-1 cells (40,46). The FC results showed that QDs-
OCD had a higher internalization into human HeLa cells than
into U-87 and BON-1 cells. This could be attributed to the
higher expression of SSTR2 in HeLa cells compared with the
limited expression observed in the U-87 cell line (Fig. 3) (1).
In Vivo Targeting of Octreotide-Coated QDs
Animal work showed a significantly (p ≤ 0.05, ANOVA/Tukey)
higher accumulation of Cd in the blood comparedwith the other
tested organs, such as the liver and spleen, which represent
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digested QDs in the blood (Fig. 4). Approximately 51.78 ± 3.4%
injected dose per gram of tissue (ID/gtissue) of QDs-OCD was
found in the blood compared to 21.56± 1.3% and 7.5 ± 1.22%
of QDs-OCD found in the liver and spleen, respectively, from
the total amount of Cd detected. An in vivo study revealed
inhibition of non-specific internalization of QDs-OCD
into the liver compared with unmodified QDs. CLSM
(Fig. 5) also confirmed this result; liver cells showed no
accumulation of QD-OCD particles and subsequently
did not detect fluorescence. On the other hand, the
particles fluoresced in liver cells in the case of unmodified
QDs, which suggested the metabolization of the unmodified
QDs. It is also worth noting that the QDs-OCD found in the
blood had a fluorescence peak corresponding to that obtained
from the unmodified QDs using ICP-MS (Fig. 4).
Furthermore, no QDs were detected in the blood of the pla-
cebo mouse serum.
The presence of QDs-OCD in blood was also confirmed
by measurements of the fluorescence of injected QDs-OCD
compared to the unmodified QDs as shown in the fluores-
cence spectra obtained from the blood of mice injected with
QDs-OCD compared to that of unmodified QDs. Moreover,
the data obtained from placebo mouse serum showed no fluo-
rescence and no interference with natural QD fluorescence
(Fig. 6). These findings confirmed the large accumulation of
QDs-OCD in blood cells due to the overexpression of SSTR2.
Fig. 3 The binding capacity of
QDs-OCD with different investi-
gated cell lines as obtained from the
flow cytometry study. The binding
was reduced in the case of incuba-
tion with 100 μM free OCD. *
Statistically significant uptake with
HeLa cells (p≤ 0.05, ANOVA/
Tukey) compared to Bon-1 and U-
87 cells. Each data point denotes
the average of three measurements
(±SEM).
(a) Control (No QDs) (c) 20 nM QDs-OCD
(b) 20 nM QDs (unmodified) (d) 20 nM QDs-OCD + 100 µM free OCD
Fig. 2 CLSM images showing the
binding of QDs to BON-1 cells.
BON-1 cells were incubated with
(a) the only medium, (b) QDs (un-
modified), (c) the formulated QDs-
OCD, and (d) the formulated
QDs-OCD in the presence of free
peptide. Each picture is presented
as brightfield vs darkfield.
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DISCUSSION
Active targeting to specific kinds of cells and/or receptors has
gained increasing attention from researchers working with
different organ disorders and cancers, especially compared
with passive targeting. Additionally, the carrier system is very
important as the receptor analogue for efficient targeting and
therapy. Coupling between the targeting moiety and the
carrier depends on the chemical structure, reaction medium,
and availability of selective groups for conjugation. In this
study, OCD was conjugated with QDs-PEG amine
(unmodified) at the selective N-terminus of OCD under low
pH conditions to produce an effective targeting moiety, QDs-
OCD, in a stable colloidal dispersion. Many groups could
affect the reaction and formation of conjugates, such as
sulfhydryl groups, which are essential for the completion of
(a) Liver tissues & 
Unmodified QDs
(b) Liver tissues &
QDs-OCD
Fig. 5 Mouse liver tissues were
examined using CLSM after
treatment with 100 pmole
unmodified QDs and QDs-OCD.
(a) Unmodified QDs showed a
huge accumulation in liver tissues,
whereas (b) QDsOCD did not
appear in the liver tissues.
Fig. 4 Unmodified QDs and QDs-OCD bio-distribution in the investigated mouse organs. The measured cadmium amount demonstrates the QD content,
whereas ICP-MS was used to determine the amount of Cd to represent the amount of QDs-OCD. * Significant (p≤ 0.05, ANOVA/Tukey) distribution of QDs-
OCD in the blood compared to other organs; ** Significant (p≤ 0.05, ANOVA/Tukey) distribution of QDs-OCD in the compared to the other organs. Each data
point denotes the average of three measurements (±SEM).
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the conjugate. Hence, the addition of EDTA to the reaction
medium to chelate all divalent metal ions that can oxidize
sulfhydryl groups (6) makes the reaction much more selective.
FT-IR spectroscopy and 1H-NMR confirmed the attachment
of OCD to QDs. The 1H-NMR showed the proton signals of
OCD and succinate. In addition, FT-IR showed two carbonyl
groups reflecting the covalent bond formation in the conju-
gated QDs-OCD compared to the physical mixture between
the respective components which is not confirmed.
Generally, the particle surface charge and the degree of
zeta potential confirm the stability of the colloidal system.
The scale of the zeta potential reveals the grade of electrostatic
repulsion between neighbouring like charged particles in a
dispersion. The prepared QD-OCD conjugate had enough
repulsive forces between particles, hence the stability of the
prepared colloidal solution (3). Moreover, colloids with high
zeta potentials (negative or positive) are considered electroni-
cally stabilized, while low zeta potentials lead to coagulation
or flocculation of the dispersion medium (45,55). It is also
worth noting that a reversal of zeta potential from a negative
to a positive value for the unmodified QDs and QDs-OCD,
respectively, suggested that the OCD bound to QDs (26).
However, a significant blueshift for the formulated QDs-
OCD confirmed that the unmodified QDs was conjugated
to OCD. Interestingly, despite the successful conjugation be-
tween the QDs and OCD, the conjugate did not disturb or
affect the fluorescence activity of unmodified QDs.
CLSM results supported the results obtained and con-
firmed that the produced QDs-OCD were actively trans-
ported into the investigated cells through interaction with
the targeted SSTR2 embedded into the cell surface. QDs-
OCD were detectible in the cytoplasm of cells upon
receptor-mediated endocytosis. Additionally, the fluorescence
spectra obtained from FACS confirmed that the particles had
the same original fluorescence corresponding to those ob-
served by CLSM. Much more evidence was also gained after
studying the internalization capacity using different cell lines
with different expression patterns of SSTR1–5. QDs-OCD
demonstrated significant internalization with cells that express
more receptors on their surface, such as HeLa cells, compared
with U-87 cells. Hence, there was selectivity of the produced
QDs-OCD system. The higher expression of mRNA in cells
containing higher amounts of SSTR2, such as HeLa cells,
could also be the cause behind the higher internalization com-
pared with cells showing a lower expression of SSTR mRNA,
such as U-87 cells. Furthermore, the fluorescence intensities of
QDs-OCD in HeLa cells, U-87 cells, and BON-1 cells were
equivalent to those obtained by RT-PCR in our lab (11).
Similar results have also been reported regarding gold NPs
coated with SST analogues targeting SSTR1–5 (1,6).
Interestingly, QDs-OCD showed very low internalization
and/or hindrance to transport into the target cells upon the
addition of higher amounts of free OCD for blocking the
SSTR2, which means that the higher internalization of par-
ticles was due to transport through interaction with SSTR2.
The large Cd content in the blood is due to the circulation of
OCD-coated QDs as the OCD bound to the SSTR2 in blood
cells (2). It has been reported that SSTR1–5 are overexpressed
on the surface of monocytes (14,39,42,47,48,52,59).
Hence, these QDs-OCD facilitate targeting and early diag-
nosis of leukaemia. The formulated system could also have the
potential for a long circulation time in the blood and a long life-
span in monocytes, as the OCD was conjugated to the QDs via
space from the PEG-amine. (30). The PEG layer around theNPs
can reduce the adsorption of opsonins and the rapid clearance of
NPs, which is preferred in cancer therapy (53,58,61). On the
other hand, unmodified QDs accumulated in the liver due to
rapid lymphatic uptake and non-binding to SSTR1–5. (2). The
impact of this finding is the accumulation ofQDs-OCD in blood.
Pollinger et al. formulated the QDs as RGD-modified QDs (50),
the study showed a large accumulation of unmodified QDs as





















QDs-PEG amine (unmodified QDs)
QDs-OCD
Serum of control mouse
Fig. 6 Fluorescence spectrum of
QDs-OCD in the blood compared
with 20 nM unmodified QDs, and
serum of control mouse.
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amounts were found in blood. The liver accumulated 50.1%
ID/gtissue, the spleen accumulated 29.36% ID/gtissue, while only
11.8% ID/gtissue circulated in the blood. Results showed that
OCD can target the blood with avoidance of toxic effect on
the liver. All other organs showed negligible uptake of QDs-
OCD (supplementary 3). While lung showed some accumula-
tions of QDs-OCD which also due the expression of SSTR 1–5
on lung cells (33,38). This kind of targeting is selective, very
specific and has the potential to target blood cell diseases such
as leukaemia. Further studies will proceed in leukaemicmodels to
investigate the potential of the prepared system for the treatment
of blood cancer and effective therapy compared with other pos-
sible medications.
CONCLUSIONS
QDs were successfully conjugated with OCD to give a stable
colloidal dispersion, as indicated from the emission absorption
spectra. QDs-OCD could target and bind selectively with cells
expressing higher amounts of SSTR2, such as HeLa cells,
compared with those expressing lower amounts of SSTR2,
e.g., U-87 cells. Moreover, the produced system had superior
potential for targeting blood monocytes than other organs,
such as the liver, spleen, and eye. The formulated QDs-
OCD showed a minimum clearance from blood monocytes
via the lymphatic system to drain into the liver. As well as they
remained in the blood for a relatively long time as measured
from 3 h experiment time. Future studies will consider the
effectiveness of the proposed system in different organs with
empathize on the toxicity and pharmacokinetic profiles
manipulations. Hence, this system offers a great advantage
for selective targeting of blood cells with higher therapeutic
efficiency.
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